

RECEIVED  
2007 APR -3 P 2:33  
OFFICE OF INTERNATIONAL  
CORPORATE FINANCE



CARL ZEISS MEDITEC

Carl Zeiss Meditec AG 07740 Jena Germany  
Securities and Exchange Commission  
Division of Corporation Finance  
Office of International Corporate Finance  
100 F Street, N.E.

Carl Zeiss Meditec AG  
Goeschwitzer Strasse 51-52  
07745 Jena  
Germany

Tel: +49 (0) 36 41/220-105

Fax: +49 (0) 36 41/220-117

e-mail: j.brajer@meditec.zeiss.com

Washington, D. C. 20549-3628  
United States

Mailstop: Room 3628



SUPL

Division/ Dept.: Investor Relations  
Your contact: Jens Brajer

Our ref.: JB/Yei

Date: 2007-03-13

File No. 82-34817

Dear Ladies and Gentlemen,

Please find attached the following documents that were released to our shareholders:

Type of document
Press Release

PROCESSED

APR 11 2007

THOMSON  
FINANCIAL

Best regards,

Carl Zeiss Meditec AG

Jens Brajer  
Director Investor Relations

Yvonne Eisner  
Assistant Investor Relations

Board of Management:  
Ulrich Krauss (CEO)  
Bernd Hirsch  
James L. Taylor  
Chairman of the Supervisory Board:  
Dr. Michael Kaschke

Deutsche Bank AG Jena  
Account: 62 453 69 (BLZ: 820 700 00)  
SWIFT: DEUT DE 8E  
IBAN: DE90820700000624536900  
Commercial register:  
Jena, HRB 205623  
VAT-IdNo. DE 811 922 737  
Tax-No. 64003/ 02707

Commerzbank Jena  
Account: 258072800 (BLZ: 820 40000)  
SWIFT: COBADEFFXXX  
IBAN: DE3 1820400000258072800  
Phone: +49 (0) 36 41/ 220-0  
Fax: +49 (0) 36 41/ 220-112  
Internet: www.meditec.zeiss.com  
e-mail: info@meditec.zeiss.com



## **Carl Zeiss Meditec: Shareholders confirm the company's growth course**

**(Jena, 12 March 2007)** At the Annual General Meeting in Jena last Friday, the shareholders of the medical technology manufacturer Carl Zeiss Meditec AG (ISIN DE0005313704), listed in the TecDAX index of the German Stock Exchange, approved all of the day's proposed agenda items with an overwhelming majority. In doing so, they testified to the profitable growth course that the company has been successfully pursuing for many years now.

The shareholders also approved the resolution on the utilisation of profits for financial year 2005/2006. Carl Zeiss Meditec can therefore today distribute a dividend of € 0.14 per share. This dividend payment also extends to the shares that were newly issued at the end of last year.

The Management Board made a detailed presentation of the key data of the Company's economic development to the approximately 300 shareholders and guests present. They learned how during the past financial year 2005/2006, the Jena-based medical technology company boosted its sales by around 21% to € 390.6 million and once again improved its profitability year-on-year. In his report, CEO Ulrich Krauss explained that Carl Zeiss Meditec has also continued its positive growth during the first quarter of financial year 2006/2007: in addition to the company's organic growth, the first-time inclusion of Carl Zeiss Surgical in the consolidated financial statements of Carl Zeiss Meditec also produced a jump in both sales and earnings.

For the current financial year 2006/2007 the company anticipates a sales plus at least in line with average market growth levels. "We expect Carl Zeiss Meditec's profitability to continue to grow", forecasts Ulrich Krauss.

**Press Release**



**Brief profile**

Built on an unparalleled 160-year heritage of optical innovation, Carl Zeiss Meditec AG (International Securities Identification Number DE0005313704) is one of the world's leading eye care solutions providers.

Its product line includes systems for the diagnosis and treatment of the four main diseases of the eye: vision defects (refraction), cataracts, glaucoma and retinal disorders. The company has incorporated its technological expertise into a stream of product innovations throughout the years, from slit lamps and fundus cameras; to the Humphrey® Field Analyzer, recognised as the global standard for glaucoma detection and management; to its newest applications of lasers as embodied in its leading-edge MEL 80™ refractive laser and innovative STRATUSOCT™ device for glaucoma diagnosis. Since 2005, the company has also been present in the market for intraocular lenses and consumables, and now covers almost the entire value chain of ophthalmic surgery. The company is looking to continue its profitable growth in the future. The acquisition of Carl Zeiss Surgical further supplements the ophthalmic surgery product portfolio and opens up additional growth prospects in neuro and ENT surgery. Carl Zeiss Surgical is the world's leading provider of visualisation solutions in both these fields.

Carl Zeiss Meditec AG is based in Jena, Germany, with subsidiaries in Germany (Carl Zeiss Surgical GmbH and Carl Zeiss Meditec Systems GmbH), the USA (Carl Zeiss Meditec Inc. and Carl Zeiss Surgical Inc.), in Japan (Carl Zeiss Meditec Co., Ltd.), Spain (Carl Zeiss Meditec Iberia S.A.) and France (Ioltech S.A., Carl Zeiss Meditec France SAS). The rapidly aging global population and other trends are expected to grow the ophthalmic market in the long term. The company is focused on applying innovative optical technologies to protect and enhance vision now and into the future.

Thirty-five percent of the Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss, one of the world's leading international groups engaged in the optical and opto-electronics industry.

**Contact**

Jens Brajer/ Director Investor Relations  
Goeschwitzer Straße 51-52  
07745 Jena, Germany

Telefon: +49 (0) 36 41 - 2 20 - 1 05  
Telefax: +49 (0) 36 41 - 2 20 - 1 17

E-Mail: [investors@meditec.zeiss.com](mailto:investors@meditec.zeiss.com)  
Web: <http://www.meditec.zeiss.com>

**Press Release**



## **Carl Zeiss Meditec enjoys unscheduled inclusion in TecDAX**

**(Jena, 2 March 2007)** As part of an unscheduled amendment, the medical technology manufacturer Carl Zeiss Meditec AG (ISIN DE0005313704) is to be included in Deutsche Boerse's TecDAX index from March 5, 2007. Deutsche Börse notified Carl Zeiss Meditec of this move on 1 March 2007.

"We are very pleased with this news. Our inclusion in the TecDAX means we have achieved one of the key goals of our investor relations work – a goal we've been pursuing for some time," commented Ulrich Krauss, President and CEO of Carl Zeiss Meditec AG. "This is based on our company's significant growth over the past few years as well as the increased internationalisation of our shareholder basis, not to mention transparent, in-depth communications with the capital market. Of course we will continue and further expand this communication in future."

**Press Release**

### **Brief profile**

Built on an unparalleled 160-year heritage of optical innovation, Carl Zeiss Meditec AG (International Securities Identification Number DE0005313704) is one of the world's leading eye care solutions providers.

Its product line includes systems for the diagnosis and treatment of the four main diseases of the eye: vision defects (refraction), cataracts, glaucoma and retinal disorders. The company has incorporated its technological expertise into a stream of product innovations throughout the years, from slit lamps and fundus cameras; to the Humphrey® Field Analyzer, recognised as the global standard for glaucoma detection and management; to its newest applications of lasers as embodied in its leading-edge MEL 80™ refractive laser and innovative STRATUSoct™ device for glaucoma diagnosis. Since 2005, the company has also been present in the market for intraocular lenses and consumables, and now covers almost the entire value chain of ophthalmic surgery. The company is looking to continue its profitable growth in the future. The acquisition of Carl Zeiss Surgical further supplements the ophthalmic surgery product portfolio and opens up additional growth prospects in neuro and ENT surgery. Carl Zeiss Surgical is the world's leading provider of visualisation solutions in both these fields.

Carl Zeiss Meditec AG is based in Jena, Germany, with subsidiaries in Germany (Carl Zeiss Surgical GmbH and Carl Zeiss Meditec Systems GmbH), the USA (Carl Zeiss Meditec Inc. and Carl Zeiss Surgical Inc.), in Japan (Carl Zeiss Meditec Co., Ltd.), Spain (Carl Zeiss Meditec Iberia S.A.) and France (Ioltech S.A., Carl Zeiss Meditec France SAS). The rapidly aging global population and other trends are expected to grow the ophthalmic market in the long term. The company is focused on applying innovative optical technologies to protect and enhance vision now and into the future.

Thirty-five percent of the Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss, one of the world's leading international groups engaged in the optical and opto-electronics industry.

### **Contact**

Jens Brajer/Director Investor Relations  
Goeschwitzer Strasse 51-52  
07745 Jena

Phone: +49 (0) 36 41 - 2 20 - 1 05  
Fax: +49 (0) 36 41 - 2 20 - 1 17

E-Mail: [investors@meditec.zeiss.com](mailto:investors@meditec.zeiss.com)  
Web: <http://www.meditec.zeiss.com>

*END*

**Press Release**